Metronomische Chemotherapie mit oralem Cyclophosphamid

This publication has 17 references indexed in Scilit:

• Immune checkpoint inhibitors and prostate cancer: a new frontier?
  Oncology Reviews, 2016
• DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
  New England Journal of Medicine, 2015
• Sequencing of agents in castration-resistant prostate cancer
  The Lancet Oncology, 2015
• Metronomic chemotherapy with cyclophosphamide and dexamethasone in patients with metastatic carcinoma of the prostate
  British Journal of Cancer, 2012
• Oral/metronomic cyclophosphamide-based chemotherapy as option for patients with castration-refractory prostate cancer – Review of the literature
  Cancer Treatment Reviews, 2011
• Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
  The Lancet, 2010
• New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
  European Journal of Cancer, 2009
• Low Dose Metronomic Oral Cyclophosphamide for Hormone Resistant Prostate Cancer: A Phase II Study
  Journal of Urology, 2007
• Metronomic therapy with cyclophosphamide and dexamethasone for prostate carcinoma
  Cancer, 2003
• A Controlled Trial of Leuprolide with and without Flutamide in Prostatic Carcinoma
  New England Journal of Medicine, 1989